UK Parliament Backbench Debate: Is WHO Really Doing Good for Human Health?

Special Report by Charlotte Yu
Jan.19.2024
UK Parliament Backbench Debate: Is WHO Really Doing Good for Human Health?
Without tax (price) incentives and flavor differentiation compared to traditional cigarettes, there would be little motivation for people to quit smoking.

A backbench debate was held on Jan 18 in the UK Parliament as the tenth session of the Conference of the Parties to the Framework Convention on Tobacco Control (COP10) is scheduled to take place in Panama from February 5 to 10, and the UK will be sending a delegation.

 

The debate, initiated by Members of Parliament Andrew Lewer, Mr. Virendra Sharma, and Martyn Day, aimed to challenge the WHO's opposition to e-cigarettes, focusing on the regulation of e-cigarettes in the UK, the World Health Organization (WHO), and the differing stances of the organization and the UK government on e-cigarettes.

 

The WHO for a long time has been committed to controlling the use of tobacco and nicotine products, particularly e-cigarettes. According to reports from December 14, 2023, the organization emphasized the need for urgent action to control e-cigarettes, aiming to protect children and non-smokers while minimizing health risks to the public. The WHO pointed out that the nicotine present in e-cigarettes is highly addictive and harmful to health.

 

During the debate on Thursday, Member of Parliament Andrew Lewer argued against this perspective. He cited research from Cancer Research UK, stating that "it's not nicotine but the chemicals produced during the combustion of tobacco that cause lung cancer."

 

Based on this theoretical finding, MP Andrew Lewer throughout the debate addressed vaporized e-cigarettes as "tobacco harm reduction products," aligning with the broader direction of the UK government's tobacco control policy. He insisted on two central arguments. First, new tobacco products, including vaporized e-cigarettes, should not be subject to the same tax rates as traditional cigarettes. Second, flavored vaporized e-cigarettes should not be banned. He argued that without tax (price) incentives and flavor differentiation compared to traditional cigarettes, there would be little motivation for people to quit smoking.

 

UK Parliament Backbench Debate: Is WHO Really Doing Good for Human Health?
Andrew Lewer, a member of parliament who spoke in the backbench debate on January 18th | Image source: 2FIRSTS

 

In addition to urging the UK delegation to maintain its stance on the smoking cessation role of e-cigarettes in international conferences, Andrew Lewer also questioned the entire WHO institution during the debate and raised the issue of whether the UK should review the scale of its donations to the organization. This is because the UK is currently one of the largest funders of the WHO, and there is a need to ensure that "taxpayers' money is well utilized."

 

Later in the debate, co-initiator Virendra Sharma stated, "COP10 and WHO should not make it harder for those who want to quit smoking with e-cigarettes." Therefore, policies that excessively regulate e-cigarettes, heated tobacco, and oral nicotine pouches are worthy of debate.

 

He also mentioned that although the UK is a global leader in tobacco harm reduction policies, it can still learn from other countries' successful experiences in using new nicotine products to control smoking. He cited Japan and Sweden as examples where heated tobacco and oral snus significantly reduced smoking rates. There are better ways for the UK to achieve a better outcome through compromise.

 

Labour politician and Member of Parliament for Bristol South, Karin Marguerite Smyth, also participated in the debate. After expressing anticipation for the UK delegation's participation in the treaty conference and conveying the country's voice, she mentioned that many MPs have received letters from constituents inquiring about e-cigarettes and smoking because it will be a central topic at COP10. Voters are concerned about whether this conference will change the future use of e-cigarettes by British citizens. She asked the Minister of Public Health if there are plans to include other nicotine products in the upcoming government bill's regulatory process.

 

UK Parliament Backbench Debate: Is WHO Really Doing Good for Human Health?
Virendra Sharma | Image source: 2FIRSTS

 

The responsibility of responding to inquiries in this debate fell on Dame Andrea Jacqueline Leadsom, who has taken office as the Deputy Minister of Public Health, Start for Life, and Primary Care since November 2023. She expressed opposing views to some points raised by the aforementioned MPs.

 

Using her own experience of teenage smoking and the challenging process of quitting, she stated that claiming nicotine is entirely harmless is "wrong" and reiterated the addictive nature of nicotine. She also raised some questions, mentioning that flavors like cherryade and bubble-gum are not designed for adults. These flavors and packaging resembling little Coke bottles or brightly colored like bubble-gum are clearly "aimed at children." The fact that e-cigarettes are placed next to candies, sold conveniently at pocket-money prices is concerning. Therefore, she urged MPs not to "naively look at this issue" and emphasized that only strong enforcement measures can ensure that e-cigarettes are not sold to minors.

 

UK Parliament Backbench Debate: Is WHO Really Doing Good for Human Health?
Dame Andrea Jacqueline Leadsom who spoke in the back seat debate on January 18th | Image source: 2FIRSTS

 

Regarding the upcoming COP10, she described the UK as a "unique case" on the issue of e-cigarettes and stated that the country will present its position at the conference, emphasizing that e-cigarettes are a crucial tool to help adults quit smoking. "But as for whether there should be a change in the current level of donations to the WHO, the UK government tends to maintain the existing level." She concluded by stating that she will provide a statement to the Parliament after COP10 to update on the proceedings.

 

E-cigarettes in Backbench Debates

 

This is not the first time tobacco (or novel tobacco) has appeared in backbench debates in the UK.

 

Backbench debates, also known as Westminster Hall debates, allow MPs to raise local or national issues and receive responses from government ministers.

 

According to incomplete statistics, in June 2020, government MPs revolted against the ban on people importing liquid nicotine for e-cigarettes; on November 3, 2022, the House of Commons debated the Independent Review of Smokefree 2030 policies; and earlier this week, there was another debate on e-cigarettes. On January 16, a debate hosted by Conservative MP Peter Gibson discussed issues related to illicit (gray) market vaping products and underage illegal vaping.

 

The UK's stance on novel tobacco, especially e-cigarettes, has consistently differed from the WHO's perspective. The UK government has been supportive of e-cigarettes as an alternative to reduce the harm of smoking. According to the UK government's viewpoint, e-cigarettes can help smokers quit, and their harm is much lower than that of traditional tobacco products.

 

A report from Policy Exchange indicates that smoking has a significant impact on the economy, and reducing smoking rates not only improves health conditions and alleviates the burden on the national health service but also promotes productivity and economic growth.

 

2FIRSTS will continue to monitor the upcoming Conference of the Parties to the WHO Framework Convention on Tobacco Control (COP10) in Panama, as well as developments in UK tobacco control policies and regulations for both traditional and novel tobacco products.

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

JAMA Study: U.S. Vape Directories Fail to Sustainably Curb Unlisted Sales as Product Shifts May Redistribute Brand Share 2Firsts Recommended
JAMA Study: U.S. Vape Directories Fail to Sustainably Curb Unlisted Sales as Product Shifts May Redistribute Brand Share 2Firsts Recommended
A study by CDC Foundation researchers found no sustained decline in e-cigarette sales across Alabama, Oklahoma and Louisiana, the first three U.S. states to implement e-cigarette directory laws. Louisiana initially saw a significant sales decline, followed by a rebound and a persistent reduction in product availability. Sales also shifted from nontobacco-flavored disposables toward prefilled cartridges, with Vuse Alto driving much of the increase in menthol cartridges. By April 2025, unlisted products still accounted for more than half of e-cigarette nicotine sales in all three states.
Sep.18
Australian Coalition Unveils Illicit Tobacco Plan With 80% Excise Cut and Legal, Taxed Vapes and Nicotine Pouches
Australian Coalition Unveils Illicit Tobacco Plan With 80% Excise Cut and Legal, Taxed Vapes and Nicotine Pouches
Australia’s Coalition has unveiled a national illicit-tobacco policy that would cut tobacco excise by 80% and create legal, regulated and taxed adult markets for vaping products and nicotine pouches if it wins government. The plan proposes an excise of A$0.50 per millilitre of e-liquid and A$0.025 per milligram of nicotine in pouches, alongside A$200 million in additional enforcement and a A$60 million three-year public-awareness campaign. The Coalition says the package would narrow the price advantage of illicit products and undermine organised crime, while Labor and public-health groups warn that dramatically cheaper cigarettes could reverse long-term declines in smoking.
Sep.03
As Regulators Focus on Nicotine Pouch Child Safety, Safeguard Pursues an External Packaging Route
As Regulators Focus on Nicotine Pouch Child Safety, Safeguard Pursues an External Packaging Route
As regulators pay closer attention to child safety in nicotine pouches, manufacturers face a practical challenge: how to strengthen child-resistant packaging without unnecessarily reworking products, production lines and regulatory submissions already in place. In a written interview with 2Firsts, Chemular detailed Safeguard’s external packaging approach, its customer-specific testing requirements and possible PMTA pathways. The model remains early-stage, but it offers a new way to think about an increasingly important regulatory and manufacturing issue.
Industry Insight
Sep.19
Kumulus Vape2026 H1 Revenue Falls 8.3% but Profit Rises 24% as B2B Weakens and Consumer Channels Grow
Kumulus Vape2026 H1 Revenue Falls 8.3% but Profit Rises 24% as B2B Weakens and Consumer Channels Grow
French vaping company Kumulus Vape reported first-half 2026 revenue of €25.5 million, down 8.3% year over year, as its core B2B distribution business fell 11% to €21.6 million. B2C and store-network revenue rose 5.6% and 17.8%, respectively. Commercial margin increased to 26.3% from 21.7%, while net profit rose 24.1% to €0.8 million. The company attributed the profitability improvement to catalog optimization, logistics restructuring and the ramp-up of Labster, its in-house production unit for proprietary brands.
Market
Sep.17 by 2Firsts Perspectives
Product | PIXL Adds 6ml PIXL 5K in UK Alongside 12ml PIXL 8000 as Vape Duty Takes Effect
Product | PIXL Adds 6ml PIXL 5K in UK Alongside 12ml PIXL 8000 as Vape Duty Takes Effect
Vaping brand PIXL has introduced the PIXL 5K reusable prefilled pod device in the UK, featuring a 2ml prefilled pod and a 4ml refill container with a combined e-liquid capacity of 6ml. The device uses 20mg/ml nicotine salt e-liquid and is advertised to deliver up to approximately 5,000 puffs. Available through UK retailers by August 2026, the PIXL 5K sits alongside the existing 12ml PIXL 8000. The UK's Vaping Products Duty took effect on October 1 at £0.22 per millilitre, producing theoretical duty amounts of £1.32 and £2.64 for the two products' respective full refill sets.
product
Oct.10
PMI Showcases ZYN, IQOS and U.S. Investments at NACS Show 2026
PMI Showcases ZYN, IQOS and U.S. Investments at NACS Show 2026
At the 2026 NACS Show in Las Vegas, Philip Morris International (PMI) showcased its ZYN nicotine pouches, IQOS heated tobacco products and U.S. investments. A 2Firsts review of FDA records found that several ZYN products displayed at the booth were not on the agency's marketing authorization list, including certain nicotine strengths and flavors. A PMI booth representative also confirmed that IQOS is currently sold in three U.S. states, while the newer IQOS ILUMA system remains under FDA review.
EXPO
Oct.10